Dynavax Technologies (NASDAQ:DVAX) Announces Earnings Results

Dynavax Technologies (NASDAQ:DVAX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05, Zacks reports. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%.

Dynavax Technologies Stock Performance

Dynavax Technologies stock traded up $0.25 during mid-day trading on Thursday, reaching $13.34. 1,866,150 shares of the company traded hands, compared to its average volume of 1,785,707. The firm’s fifty day moving average is $12.80 and its two-hundred day moving average is $11.98. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 102.58 and a beta of 1.32. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $13.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Wall Street Analyst Weigh In

Several research analysts recently commented on DVAX shares. HC Wainwright boosted their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.